Completed PHASE1 INTERVENTIONAL 3-arm NCT03555617

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

A Phase 1, Open-Label, 2-Cohort Study to Assess the Single Dose Pharmacokinetics of Two Formulations of TD-1473 and to Assess the Effect of a High-Fat Meal and Itraconazole on the Pharmacokinetics of TD-1473 in Healthy Subjects

Sponsor: Theravance Biopharma

Conditions Inflammatory Bowel Disease

Interventions Itraconazole TD-1473

Updated 7 times since 2018 Last updated: Jan 12, 2021 Started: Jun 13, 2018 Primary completion: Jul 15, 2018 Completion: Jul 15, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03555617, this PHASE1 trial focuses on Inflammatory Bowel Disease and remains completed. Sponsored by Theravance Biopharma, it has been updated 7 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Feb 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Feb 2021 [monthly]

Completed PHASE1
Feb 2020 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Oct 2018 — Feb 2020 [monthly]

Completed PHASE1

Status: Not Yet Recruiting → Completed
Jul 2018 — Oct 2018 [monthly]

Not Yet Recruiting PHASE1

First recorded

Jun 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Theravance Biopharma

Data source: Theravance Biopharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lincoln, United States